Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to Chi et al.: Defining <i>BRCA1P1</i> as a tumor-intrinsic immunoregulatory axis in breast cancer.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Polygenic Risk Scores for Breast Cancer Among African American Women With High Risk.

JAMA network open·2026
Same author

Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations: A Secondary Analysis of the WISDOM Study.

JAMA oncology·2026
Same author

Multi-ancestry transcriptome-wide association studies uncover insights into breast cancer genetics and biology.

Nature communications·2026
Same author

Accessible Clinical Tool for Prognosis and Chemotherapy Prediction in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer in Diverse and Low-Resource Settings.

JCO global oncology·2026
Same author

Pragmatic Clinical Trial Assessing Response to Neoadjuvant Docetaxel and Trastuzumab in Nigerian Women With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer (ARETTA).

JCO global oncology·2026

Related Experiment Video

Updated: Jun 28, 2026

The Use of Mouse Mammary Tumor Cells in an In Vitro Invasion Assay as a Measure of Oncogenic Cell Behavior
08:12

The Use of Mouse Mammary Tumor Cells in an In Vitro Invasion Assay as a Measure of Oncogenic Cell Behavior

Published on: June 12, 2019

MYC in breast tumor progression.

Yinghua Chen1, Olufunmilayo I Olopade

  • 1Department of Medicine, Center for Clinical Cancer Genetics, University of Chicago, Chicago, IL 60637, USA. ychen@medicine.bsd.uchicago.edu

Expert Review of Anticancer Therapy
|October 18, 2008
PubMed
Summary

MYC amplification in breast cancer is linked to aggressive tumors and poor outcomes. This finding highlights MYC as a potential biomarker for targeted therapies, especially in BRCA1-associated and triple-negative breast cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Breast cancer is a leading cause of death in women, characterized by genetic and epigenetic alterations driving malignancy.
  • MYC, a proto-oncogene and transcription factor, regulates a significant portion of human genes, influencing cell growth, transformation, and angiogenesis.
  • MYC dysregulation is implicated in aggressive breast cancer phenotypes and poor clinical outcomes.

Purpose of the Study:

  • To investigate the role of MYC amplification in breast cancer progression and its correlation with clinical outcomes.
  • To explore the significance of MYC as a potential biomarker for predicting response to HER2-targeted therapies.
  • To understand the role of MYC in BRCA1-associated and basal-like/triple-negative breast cancers.

Main Methods:

More Related Videos

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Experiment Videos

Last Updated: Jun 28, 2026

The Use of Mouse Mammary Tumor Cells in an In Vitro Invasion Assay as a Measure of Oncogenic Cell Behavior
08:12

The Use of Mouse Mammary Tumor Cells in an In Vitro Invasion Assay as a Measure of Oncogenic Cell Behavior

Published on: June 12, 2019

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

  • Analysis of MYC gene amplification and its correlation with tumor phenotypes and clinical outcomes.
  • Examination of MYC's role in regulating target genes involved in cell cycle control and angiogenesis.
  • Investigation of MYC's interaction with BRCA1 in the context of breast cancer.

Main Results:

  • MYC amplification is significantly correlated with aggressive tumor phenotypes and poorer clinical outcomes in breast cancer patients.
  • MYC target genes are crucial for cell growth, transformation, and angiogenesis in breast cancer cells.
  • MYC amplification shows potential as a predictor of response to HER2-targeted therapies.

Conclusions:

  • MYC amplification is a key factor in aggressive breast cancer and is associated with poor prognosis.
  • MYC plays a critical role in breast cancer development and progression, making it a target for therapeutic strategies.
  • MYC's involvement in BRCA1-associated breast cancer underscores its importance in basal-like/triple-negative subtypes, suggesting its utility in personalized medicine.